Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Carcinoma, Renal Cell 2Bites and Stings 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Oligoprogressive 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 2Immune Checkpoint Inhibitors 2Cytochrome P-450 Enzyme System 2enzalutamide 1blinatumomab 1abiraterone 1Hydroxyurea 1Etanercept 1Androgen Receptor Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Bites and Stings × Immune Checkpoint Inhibitors × Clear all
NCT03792841 2025-10-16

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Amgen

Phase 1 Terminated
212 enrolled
Genitourinary

Bites and Stings, Prostatic Neoplasms

NCT04631601 2025-10-07

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Amgen

Phase 1/2 Terminated
65 enrolled

Bites and Stings

Data powered by HemOnc (CC BY 4.0) Colophon âš¡